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Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1,
RAD50, and CDH1 mutations in high-risk Finnish
BRCA1/2-founder mutation-negative breast and/or
ovarian cancer individuals
Kirsi M Kuusisto1,2, Aleksandra Bebel1, Mauno Vihinen1, Johanna Schleutker1,2, Satu-Leena Sallinen3*
Abstract
Introduction: Two major high-penetrance breast cancer genes, BRCA1 and BRCA2, are responsible for
approximately 20% of hereditary breast cancer (HBC) cases in Finland. Additionally, rare mutations in several other
genes that interact with BRCA1 and BRCA2 increase the risk of HBC. Still, a majority of HBC cases remain
unexplained which is challenging for genetic counseling. We aimed to analyze additional mutations in HBC-
associated genes and to define the sensitivity of our current BRCA1/2 mutation analysis protocol used in genetic
counseling.
Methods: Eighty-two well-characterized, high-risk hereditary breast and/or ovarian cancer (HBOC) BRCA1/2-founder
mutation-negative Finnish individuals, were screened for germline alterations in seven breast cancer susceptibility
genes, BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1. BRCA1/2 were analyzed by multiplex ligation-
dependent probe amplification (MLPA) and direct sequencing. CHEK2 was analyzed by the high resolution melt
(HRM) method and PALB2, RAD50, BRIP1 and CDH1 were analyzed by direct sequencing. Carrier frequencies
between 82 (HBOC) BRCA1/2-founder mutation-negative Finnish individuals and 384 healthy Finnish population
controls were compared by using Fisher’s exact test. In silico prediction for novel missense variants effects was
carried out by using Pathogenic-Or-Not -Pipeline (PON-P).
Results: Three previously reported breast cancer-associated variants, BRCA1 c.5095C > T, CHEK2 c.470T > C, and
CHEK2 c.1100delC, were observed in eleven (13.4%) individuals. Ten of these individuals (12.2%) had CHEK2 variants,
c.470T > C and/or c.1100delC. Fourteen novel sequence alterations and nine individuals with more than one non-
synonymous variant were identified. One of the novel variants, BRCA2 c.72A > T (Leu24Phe) was predicted to be
likely pathogenic in silico. No large genomic rearrangements were detected in BRCA1/2 by multiplex ligation-
dependent probe amplification (MLPA).
Conclusions: In this study, mutations in previously known breast cancer susceptibility genes can explain 13.4% of
the analyzed high-risk BRCA1/2-negative HBOC individuals. CHEK2 mutations, c.470T > C and c.1100delC, make a
considerable contribution (12.2%) to these high-risk individuals but further segregation analysis is needed to
evaluate the clinical significance of these mutations before applying them in clinical use. Additionally, we identified
novel variants that warrant additional studies. Our current genetic testing protocol for 28 Finnish BRCA1/2-founder
mutations and protein truncation test (PTT) of the largest exons is sensitive enough for clinical use as a primary
screening tool.
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Introduction
Breast cancer (BrCa) is the most common cancer among
women in Finland, with about 4,000 cases diagnosed
yearly (Finnish Cancer Registry). It has been estimated
that a monogenic trait accounts for 5 to 10% of all BrCa
cases [1]. The two major high-penetrance BrCa genes,
BRCA1 (breast cancer 1) and BRCA2 (breast cancer 2),
are responsible for 30% of hereditary breast cancer
(HBC) cases worldwide, but only for about 20% in Fin-
land [2-4]. BRCA2 mutations have been found to be
more common in the Finnish population than BRCA1
[5]. In addition to BRCA1 and BRCA2 mutations, there
are certain hereditary cancer syndromes, such as Li-
Fraumeni, Cowden, Peutz-Jeghers and diffuse gastric
cancer syndromes, associated with a high risk of BrCa
[6-9]. However, these syndromes very seldom explain
HBC.
BRCA1 and BRCA2 have many DNA damage response
functions in the cell [10]. Therefore, it has been
hypothesized that genes coding for proteins that interact
with BRCA1 or BRCA2 or act in the same DNA repair
pathway would be likely candidate genes for HBC sus-
ceptibility. As expected, CHEK2 (checkpoint kinase 2),
PALB2 (partner and localizer of BRCA2), BRIP1
(BRCA1-interacting protein 1), and RAD50 (human
homolog of Saccharomyces cerevisiae RAD50) have been
shown to have rare, moderate-risk BrCa-associated var-
iants, which have also been studied in the Finnish popu-
lation [11-14]. In addition, BrCa-associated variants have
been reported in the CDH1 (cadherin-1) [15].
Although mutations in many genes have been found
to predispose an individual to BrCa, approximately 75 to
80% of HBC cases remain unexplained [16]. It is likely
that additional BrCa susceptibility gene mutations
remain unidentified, especially in the category of moder-
ate- to low-penetrance gene variants that individually
confer only minimal risk but that, through multiplicative
and/or cumulative effects, can cause relatively high risk
for the carriers [17]. Genome-wide association studies
(GWAs) have revealed multiple low penetrance, single
nucleotide polymorphisms (SNPs) in many genes and
chromosomal loci with increased risk of BrCa. For
example, SNPs in the fibroblast growth factor receptor 2
(FGFR2) gene have shown significant association
with increased risk among BrCa cases with strong family
history [18].
To address the problem of heterogeneous HBC in
genetic counseling, we wanted to investigate possible
additional mutations in HBC-associated genes. The aim
of this study was to screen seven known BrCa suscept-
ibility genes for additional mutations in 82 well-charac-
terized, Finnish, high-risk hereditary breast and/or
ovarian cancer (HBOC) individuals tested to be BRCA1/
2-founder mutation negative. In addition, the sensitivity
of our current BRCA1/2 mutation analysis protocol was
defined for genetic counseling purposes.
Materials and methods
Patients and controls
Index individuals of 82 high-risk Finnish HBOC families
were screened for germline alterations in BrCa-asso-
ciated genes. All individuals had been detected to be
founder mutation-negative by minisequencing of the
previously known 28 Finnish BRCA1/2 mutations and
by protein truncation test (PTT) of exon 11 for BRCA1
and exons 10 and 11 for BRCA2. Study material had
been collected from the individuals, who visited the
Tampere University Hospital Genetics Outpatient Clinic
between January 1997 and May 2008. The hospital dis-
trict, in the area of Pirkanmaa, consists of over 20%
(1.23 million) of the Finnish population. Individuals
were chosen to be included in this study according to
the following criteria of high-risk HBC: (a) the indivi-
dual or her first-degree relative (only female family
members were included when defining first-degree rela-
tives) had BrCa or ovarian cancer (OvCa) at younger
than 30 years of age; or (b) two first-degree relatives in
the family had BrCa and/or OvCa and at least one of
the cancers had been diagnosed at younger than 40
years of age; or (c) three first-degree relatives in the
family had BrCa and/or OvCa and at least one of the
cancers had been diagnosed at younger than 50 years of
age; or (d) four or more first-degree relatives had BrCa
and/or OvCa at any age; or (e) the same individual had
BrCa and OvCa. Patient with bilateral BrCa was consid-
ered to have two separate cancers. According to these
criteria, our study material also included 11 non-affected
females in addition to 71 BrCa and/or OvCa patients.
We were also able to get blood samples from two
affected relatives in 2 out of 11 separate families with
healthy index. These relatives with BrCa were screened
for the same variant as that identified in the index. The
clinical data of the studied individuals are presented in
Table 1. As controls, 384 blood samples from anon-
ymous healthy females, collected from the Finnish Red
Cross, were used. All individuals have been informed of
the analyses, and they have given written consent to use
their already existing DNA samples. Permission for the
research project has been received from the Ethical
Committee of Tampere University Hospital and the
National Authority for Medicolegal Affairs.
Mutation detection
DNA samples of the individuals were kindly received
from the Tampere University Hospital Genetics Outpati-
ent Clinic. Mutation screening for BRCA1, BRCA2,
PALB2, BRIP1, RAD50, and CDH1 was performed by
direct sequencing. Whole-coding regions and exon-
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intron boundaries were analyzed. Primer sequences for
PALB2, BRIP1, and RAD50 have been reported previously
[12,13,19]. Primers for BRCA1 and BRCA2 (excluding pre-
viously analyzed exon 11 for BRCA1 and exons 10 and 11
for BRCA2) and CDH1 were designed by using Primer3
software (Rozen and Skaletsky, Whitehead Institute for
Biomedical Research, Cambridge, MA, USA) [20]. CHEK2
was screened by using high-resolution melt (HRM) analy-
sis on a Bio-Rad platform (Bio-Rad Laboratories Head-
quarters, Hercules, CA, USA). Sequencing was carried out
Table 1 Characteristics of the studied individuals
BrCa Bil. BrCa OvCa BrCa and OvCa Non-affected
Number of index individuals (n = 82) 57 8 1 5 11
Age at diagnosis
(BrCa/OvCa) n = 57 n = 16a n = 1 n = 10b -
<30 13 0 0 1 -
<40 years 11 2 0 2 -
<50 years 15 7 0 2 -
≥50 years 18 7 1 5 -
Type of BrCa n = 57 n = 16a - n = 5 -
Ductal 41 8 - 5 -
Intraductal 2 2 - 0 -
Lobular 9 3 - 0 -
Papillary 1 0 - 0 -
Medullary 1 0 - 0 -
Unknown 3 3 - 0 -
Ductal carcinomas grade known n = 38 n = 6 n = 5 -
Grade 1 7 3 0 -
Grade 2 14 3 3 -
Grade 3 17 0 2 -
ER status known n = 51 n = 11 - n = 4 -
ER + 35 10 - 2 -
ER- 16 1 - 2 -
PR status known n = 50 n = 11 - n = 4 -
PR+ 30 10 - 2 -
PR- 20 1 - 2 -
HER2, status known n = 46 n = 11 - n = 4 -
HER2+ 14 1 - 1 -
HER2- 32 10 - 3 -
Type of OvCa - - n = 1 n = 5 -
Serous - - 0 0 -
Endometrioid - - 0 0 -
Mucinous - - 0 2 -
Clear cell - - 0 1 -
Other - - 0 2 -
Unknown - - 1 0 -
Number of affected (BrCa/OvCa)
first-degree relatives n = 57 n = 8 n = 1 n = 5 n = 11
≥2 25 3 1 0 5
≥1 24 4 0 0 6
0 8 1 0 5 0
Number of affected (BrCa/OvCa)
second-degree relatives n = 57 n = 8 n = 1 n = 5 n = 11
≥2 5 0 0 0 4
≥1 11 1 0 0 0
0 41 7 1 5 7
Bil. BrCa, bilateral breast cancer; BrCa, breast cancer; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; OvCa, ovarian cancer; PR,
progesterone receptor. a8 Bilateral breast cancer cases, together 16 cancers, b5 Breast and ovarian cancer cases, together 10 cancers.
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using the Big Dye Terminator v.3.1 Cycle Sequencing Kit
and ABIPRISM 3130 × l Genetic Analyzer (Applied Bio-
systems, Foster City, CA, USA). Sequences were analyzed
with Sequencher v.4.7 software (Gene Codes Corporation,
Ann Arbor, MI, USA). Primer sequences, detailed HRM
and PCR reaction conditions are available upon request.
Control frequencies were determined for 18 variants
by HRM (CHEK2 variants), direct sequencing (BRCA1
c.4883T > C and RAD50 c.1544A > G) and TaqMan®
SNP genotyping assays (Applied Biosystems, Foster City,
CA, USA) and with an ABI7900 instrument (Applied
Biosystems, Foster City, CA, USA). Assays were already
designed and functionally tested for the following SNPs:
c.8182G > A (rs28897749), c.9976A > T (rs11571833),
c.10234A > G (rs1801426), and c.1676A > G (rs152451).
As for the c.72A > T, c.814G > A, c.1000T > G, and
c.2993G > A (rs45551636) variants, assays were designed
by Custom TaqMan® Assay Design Tool (Applied Bio-
systems, Foster City, CA, USA) according to manufac-
turer’s instructions.
The multiplex ligation-dependent probe amplification
(MLPA) analysis was performed for BRCA1 and BRCA2
(SALSA MLPA kit P002-B1 for BRCA1 (lot 0508) and
kit P090-A2 for BRCA2 (lot 0808), MRC-Holland,
Amsterdam, the Netherlands) according to manufac-
turer’s instructions and analyzed with ABIPRISM 3130xl
Genetic Analyzer and Genemapper® v.4.0 software
(Applied Biosystems, Foster City, CA, USA).
Statistical analyses
Carrier frequencies between 82 studied individuals and
384 population controls were compared by using Fish-
er’s exact test [21]. All P-values were two sided. Odds
ratios (OR) were generated by two-by-two table.
In silico prediction of novel missense variants effects
The effects of five novel-coding missense variants,
BRCA2 c.72A > T (Leu24Phe), CHEK2 c.1363G > A
(Val455Ile), PALB2 c.814G > A (Glu272Lys), PALB2
c.1000T > G (Tyr334Asp), and RAD50 c.1544A > G
(Asp515Gly), were predicted with a number of tools by
using Pathogenic-Or-Not-Pipeline (PON-P) [22]. The
predictions included those for amino acid tolerance
(programs PolyPhen version 2, Sift, PhD-SNP, SNAP)
and protein stability (I-Mutant version 3). PON-P allows
simultaneous submission of a number of variations and
proteins to selected predictors. PON-P utilizes machine
learning to combine results from several individual
predictions.
MicroRNA database and BLAST search for novel variants
MicroRNA (miRNA) target site search was performed
for the novel variant genomic positions from the micro-
RNA database (miRBase) [23]. Also BLAST search [24]
was performed for the novel human variant genomic
positions to see if these sites are conserved among dif-
ferent organisms including mouse, rat, cow, and
chicken.
Results
Index individuals of 82 high-risk HBOC families were
screened for germline alterations in BRCA1, BRCA2,
CHEK2, PALB2, BRIP1, RAD50, and CDH1 genes.
Detailed clinical information of analyzed individuals is
shown in Table 1. All of the identified 54 sequence var-
iants with their observed genotype frequencies and rs-
numbers are presented in Supplementary Table S1 in
Additional file 1. All of the identified non-synonymous
and novel sequence alterations are summarized in Table 2.
Table 2 variants are presented in Table 3 with index indi-
vidual and family cancer history. In addition, as our study
material also included healthy index individuals from 11
families, we made an effort to get blood samples from two
affected relatives in 2 out of 11 separate families. These
relatives with BrCa were screened for the same variant as
that identified in the healthy index. Analysis was per-
formed for the new cases in family 112 (CHEK2 c.470T >
C and PALB2 c.1676A > G variants) and family 231
(BRCA1 c.4883T > C variant; Table 3). In family 112, the
case proved to have the same PALB2 c.1676A > G variant
as the index individual but in family 231, the affected rela-
tive did not carry the BRCA1 c.4883T > C variant (data
not shown). To further evaluate the impact of these 11
healthy index cases, we recalculated the frequencies with-
out these 11 individuals for those variants accepted to be
meaningful for BrCa risk. Supplementary Table S2 in
Additional file 2 shows these re-calculated frequencies for
BRCA1 c.5095C > T, CHEK2 c.470T > C, and CHEK2
c.1100delC variants. No statistically significant effect was
seen for exclusion of the 11 cases.
BRCA1 and BRCA2 mutation analysis
Analysis of BRCA1 and BRCA2 revealed altogether 16 dif-
ferent sequence variants, seven in BRCA1 and nine in
BRCA2 [see Supplementary Table S1 in Additional file 1].
All but two of the identified variants in BRCA1, c.4883T >
C and c.5095C > T, have been reported to be neutral in
the databases. Heterozygous c.4883T > C variant was
observed in 4 of 82 (4.9%) women of which three had
BrCa and one had a family history of breast, cervix and
skin cancers (Tables 2 and 3). In population controls, the
frequency of the c.4883T > C variant was 6 of 367 (1.6%).
The c.5095C > T variant has been classified as a deleter-
ious mutation in the Breast Cancer Information Core
(BIC) database. The heterozygous c.5095C > T mutation
was observed in 1 of 82 (1.2%) women. The mutation car-
rying woman had BrCa diagnosed at the age of 42 years
and a strong family history of cancer (Tables 2 and 3,
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Figure 1, Family 249). Additional mutation analysis also
revealed two other affected women carrying the c.5095C >
T mutation in the same family. In BRCA2, three of the
nine identified variants were novel, c.68-80insT, c.72A > T,
and c.793 + 34T > G (Tables 2 and 3.). The heterozygous
missense variant c.72A > T (Leu24Phe), was observed in 1
of 82 (1.2%) women but not in population controls. The
c.72A > T variant carrying woman had BrCa diagnosed at
the age of 53 years. She had also two affected first-degree
relatives (mother and sister). Protein predictions by PON-P
suggested that substitution of leucine by phenylalanine in
position 24 changes significantly the properties of the side
chain and the substitution would not be tolerated. All the
other identified variants in BRCA2 have been reported pre-
viously and they are either neutral or the clinical signifi-
cance of the variants is yet uncertain especially with the
three missense variants, c.8182G > A, c.9976A > T and
c.10234A > G (Tables 2 and 3). No deletions or duplication
Table 2 Identified non-synonymous and novel sequence alterations
Carrier frequency
Gene/Nucleotide changea Effect on protein rs Numberb Individuals Controls P-values OR; 95%CI Status
BRCA1
4837A > G Ser1613Gly rs1799966 0.634 (52/82)g na - - Reportedc, d
4883T > C Met1628Thr rs4986854 0.049 (4/82) 0.016 (6/367) 0.090 3.09; 0.85-11.19 Reportedc, d
5095C > T Arg1699Trp rs55770810 0.012 (1/82) na - - Reportedc, d
BRCA2
68-80insTf - - 0.012 (1/82) na - - Novel
72A > T Leu24Phe - 0.012 (1/82) 0 (0/380) 0.177 na Novel
793 + 34T > G - - 0.012 (1/82) na - - Novel
8182G > A Val2728Ile rs28897749 0.012 (1/82) 0.003 (1/378) 0.325 4.65; 0.29-75.19 Reportedc, d
9976A > T Lys3326Stop rs11571833 0.012 (1/82) 0.029 (11/378) 0.702 0.41; 0.05-3.24 Reportedc, d
10234A > G Ile3412Val rs1801426 0.012 (1/82) 0.021 (8/379) 1.000 0.57; 0.07-4.64 Reportedc, d
CHEK2
444 + 85T > A - - 0.012 (1/82) 0.005 (2/364) 0.457 2.23; 0.20-24.94 Novel
470T > C Ile157Thr - 0.098 (8/81) 0.055 (21/381) 0.203 1.88; 0.80-4.41 Reportede
792 + 39C > T - - 0.012 (1/82) 0.021 (8/375) 1.000 0.57; 0.07-4.60 Novel
1100delCf Fs, stop at codon 381 - 0.037 (3/82) 0.016 (6/380) 0.203 2.37; 0.58-9.67 Reportede
1290T > C His430His - 0.951 (77/81)g 0.974 (372/382) 0.281 0.52; 0.16-1.69 Novel
1314T > C Asp438Asp - 0.951 (77/81)g 0.974 (372/382) 0.281 0.52; 0.16-1.69 Novel
1363G > A Val455Ile - 0.975 (79/81)g 0.976 (373/382) 1.000 0.95; 0.20-4.50 Novel
PALB2
814G > A Glu272Lys - 0.012 (1/82) 0 (0/372) 0.181 na Novel
1000T > G Tyr334Asp - 0.012 (1/82) 0.011 (4/380) 1.000 1.16; 0.13-10.52 Novel
1010T > C Leu337Ser rs45494092 0.073 (6/82) na - - Reportedc
1676A > G Gln559Arg rs152451 0.122 (10/82) 0.173 (64/371) 0.323 0.67; 0.33-1.36 Reportedc
2205A > G Pro735Pro - 0.012 (1/82) na - - Novel
2794G > A Val932Met rs45624036 0.037 (3/82) na - - Reportedc
2993G > A Gly998Glu rs45551636 0.012 (1/82) 0.038 (14/372) 0.491 0.32; 0.04-2.44 Reportedc
BRIP1
584T > C Leu195Pro rs4988347 0.024 (2/82) na - - Reportedc
2755C > T Pro919Ser rs4986764 0.390 (32/82)g na - - Reportedc
RAD50
1544A > G Asp515Gly - 0.012 (1/82) 0.010 (4/384) 1.000 1.17; 0.13-10.63 Novel
2398-32A > G - - 0.012 (1/82) na - - Novel
3475 + 33C > G - - 0.012 (1/82) na - - Novel
CI, confidence interval; Fs, frameshift; na, not analyzed; OR, odds ratio. aThe reference nucleotide sequencies were obtained from the UCSC Genome Browser [44]
and the accession numbers were following: BRCA1: [UCSC Genome Browser:NM_007295.2], BRCA2: [UCSC Genome Browser:NM_000059.3], CHEK2: [UCSC Genome
Browser:NM_007194.3], PALB2: [UCSC Genome Browser:NM_024675.3], BRIP1: [UCSC Genome Browser:NM_032043.1], RAD50: [UCSC Genome Browser:
NM_005732.3], and CDH1: [UCSC Genome Browser:NM_004360.3]. The accession numbers for the protein sequencies obtained from the Swiss-Prot Protein
knowledgebase [45] were following: BRCA1: [Swiss-Prot:P38398], BRCA2: [Swiss-Prot:P51587], CHEK2: [Swiss-Prot:O96017], PALB2: [Swiss-Prot:Q86YC2], BRIP1: [Swiss-
Prot:Q9BX63], RAD50: [Swiss-Prot:Q92878], and CDH1: [Swiss-Prot:P12830]. bThe RefSNP number, obtained from the NCBI Single Nucleotide Polymorphism
database (dbSNP) [46]. cThe NCBI dbSNP [46]. dThe Breast Cancer Information Core database [47]. eReported in the Finnish population by Vahteristo et al. [11].
fHeterozygous deletion or insertion.gDue to the high frequency of the variant observed in analyzed individuals, variant is not presented in Table 3.
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Table 3 Identified variants in the studied individuals
Family id Gene and variant Type of cancer BrCa/OvCa Histology,Grade Receptor status Other cancer cases in the family
(Age at diagnosis if available)
202 BRCA1, 4883T > C Br (26) Ductal, 3 ER-, PR-, HER2- Skin (54)
206 BRCA1, 4883T > C Br (53) Ductal, 1 ER-, PR-, HER2- Bil. Ov (64), Br (49)
231 BRCA1, 4883T > C - Br x2 (33, 46), Cer (60), Skin (73)
232 BRCA1, 4883T > C Br (34) Ductal, na ER +, PR +, HER2 na Br (39)
249 (Figure 1) BRCA1, 5095C > T Br (42) Medullary, na na Br x5 (35, 44, 57, 67, 71, ),
Co (78), Kid (67), Mel (63), Ov (45),
Skin, To (51), Ute (39)
115 BRCA2, 68-80insT Br (59) Lobular, 2 ER+, PR+, HER2- Br x3 (<50), Br x2 (60, 60)
240 BRCA2, 72A > T Br (53) Ductal, 3 ER+, PR-, HER2+ Br x2 (42, 62)
207 BRCA2, 793 + 34T > G Br (38) na na Bil. Br (64)
5 (Figure 8) BRCA2, 8182G > A - Bil. Br x2 (43, 48 and 54, 76),
BRCA2, 10234A > G Br (43), Brain (75), Lip (45), Lung (81),
Skin (75), Sto (56)
4 BRCA2, 9976A > T - Bil. Br x2 (53, 69 and <70),
CHEK2, 470T > C Br (<70)
212 CHEK2, 444 + 85T > A Bil. Br (43) Ductal, 2 and na ER+, PR+, HER2- and Br (52)
PALB2, 2794G > A na
110 (Figure 3) CHEK2, 792 + 39C > T Br (26) Ductal, 2 ER+, PR+, HER2+ Br (48), Ca (84), Pr (64)
CHEK2, 470T > C
CHEK2, 1100delC
RAD50, 2398-32A > G
112 CHEK2, 470T > C - Br x3 (35, 43, 83), Skin (76),
PALB2, 1676A > G Lung (71)
120 CHEK2, 470T > C - Br (64), Ov (72)
122 CHEK2, 470T > C Br (25) Ductal, 2 ER-, PR-, HER2+ Brain (66, Ca (83),Cer (31),
Pr (93), Re (73), Skin (87)
126 CHEK2, 470T > C Br (48) Ductal, na ER, PR, HER2 na Bil. Br, Br x2 (51, <53)
129 (Figure 2) CHEK2, 470T > C Skin (70), Lobular, 2 and ER-, PR-, HER2- and Bil. Br (59), Co (58), Skin (48)
PALB2, 1676A > G Bil. Br (78), Ductal, 1 ER+, PR+, HER2-
Sto (82)
262 (Figure 6) CHEK2, 470T > C Bil. Br Intraductal, na and ER+, PR+, HER2+ and Br (57), Panc (83), Si (79)
PALB2, 1000T > G (45, 58) Ductal, na ER+, PR+, HER2-
264 (Figure 4) CHEK2, 1100delC Bil. Br (44) Lobular, 2 ER+, PR+, HER2- Br x2 (44, 52)
265 (Figure 5) CHEK2, 1100delC Br (45) Ductal, 3 ER+, PR+, HER2+ Br (38)
PALB2, 1676A > G
237 PALB2, 814G > A Br (28) Ductal, 2 ER+, PR+, HER2+ -
133 PALB2, 1010T > C Br (48) Ductal, 2 ER+, PR+, HER2- Int, Br x2 (73, 79), Skin (60)
235 PALB2, 1010T > C Br (52) na na Bil. Br (28), Br (56)
239 PALB2, 1010T > C Br (37) Ductal, 2 ER+, PR+, HER2- Br ( > 90)
250 PALB2, 1010T > C Br (24) Ductal, 3 ER+, PR+, HER2+ Cer (30), Ov (83)
260 PALB2, 1010T > C Br (29) Ductal, 3 ER-, PR-, HER2- Br (58), Lung (60)
267 PALB2, 1010T > C Br (48) Ductal, 1 ER+, PR+, HER2 na Br x2 (51, 58)
113 PALB2, 1676A > Ga Br (51), Ductal, 3 ER-, PR-, HER2+ Br (35)
Skin (55)
131 (Figure 7) PALB2, 1676A > G Bil. Br (54) Intraductal, na and na Bil. Br (46), Br (48)
BRIP1, 584T > C Ductal, 2
229 PALB2, 1676A > G Bil. Br (68) na na Bil. Br (50, 70), Br x2 (45, 50)
236 PALB2, 1676A > G Br (29) Intraductal, na na Br (52)
246 PALB2, 1676A > G Thy (30), Ductal, 3 ER-, PR-, HER2+ Br x2 (49, 54), Re (61)
Cer (33),
Br (39)
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were identified either in BRCA1 or BRCA2 by multiplex
ligation-dependent probe amplification (MLPA).
CHEK2 mutation analysis
In CHEK2, two previously reported BrCa-associated var-
iants in the Finnish population, c.470T > C and
c.1100delC, were identified in 10 of 82 (12.1%) individuals
(Tables 2 and 3). The heterozygous c.470T > C variant
was observed in eight women of which three were healthy.
Two of the c.470T > C variant carriers had bilateral BrCa
and they carried also PALB2 missense variants (an exam-
ple of the family pedigree of the index individual carrying
the both variants is presented in Figure 2, Family 129).
The heterozygous c.1100delC variant was detected in
three women (Tables 2 and 3). One woman carrying
c.1100delC with an early-onset disease of 26 years of age
also carried the c.470T > C and the novel c.792 + 39C > T
CHEK2 variants as well as the RAD50, c.2398-32A > G
variant (Figure 3, Family 110). A second patient with the
c.1100delC variant had bilateral BrCa at the age of 44
years and two other affected individuals in her family
(mother and father’s sister; Figure 4, Family 264). A third
patient with the c.1100delC variant had BrCa diagnosed at
the age of 45 years and one affected individual (mother) in
her family. This woman carried also the PALB2 c.1676A >
G variant (Figure 5, Family 265). In addition to c.470T > C
Table 3 Identified variants in the studied individuals (Continued)
268 PALB2, 1676A > G Br (62) Papillary, na ER+, PR+, HER2- Br x2 (36, 38)
PALB2, 2205A > G
271 PALB2, 1676A > G Thy (62), Lobular, 2 ER+, PR+, HER2- Br x2 (43, 44)
Br (65)
102 PALB2, 2794G > A Br (29) Lobular, na ER-, PR-, HER2+ Br (72)
BRIP1, 584T > C
244 PALB2, 2794G > A Br (45) Ductal, 2 ER+, PR+, HER2- Bil. Br (<45), Br x2 (<35, 46),
Brain (67)
270 PALB2, 2993G > A Br (66) Ductal, 3 ER+, PR+, HER2- Br x2 (48, <66)
257 RAD50, 1544A > G Br (39) Lobular, 2 ER+, PR+, HER2- Br (69)
225 RAD50, 3475+33C > G Br (43) Ductal, 1 ER+, PR+, HER2- Br x2 (52, 77), Kid (64)
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; na, not available; Bil, Bilateral; Br, breast; Ca, cancer with
unknown primary site; Cer, cervix; Co, colon; Int, intestines; Kid, kidney; Mel, melanoma; Ov, ovary; Panc, pancreas; Pr, prostate; Re, rectum; Si, Sigma; Sto,
stomach; Thy, thyroid; To, tongue; Ute, uterus. aHomozygous variant. Cancers diagnosed in the paternal side of the family are presented in italics. Cancers diagnosed
in siblings or their children of the index patients are underlined. Cancers diagnosed in the children of the index patients are presented in bold.
Br 42
Br 44
Br 71
Co 78
Skin Mel 63 Br 57 Ute 39
Br 67
Kid 67
To 51Br 35Ov
45 BRCA1, c.5095C>T
BRCA1, c.5095C>T
72
BRCA1, c.5095C>T
Family 249
Figure 1 Family 249 pedigree. Family pedigree of the index individual with the identified BRCA1 c.5095C > T variant (same variant was also
identified in the daughter of the index individual and in the daughter of the index individual’s paternal uncle). Individuals with breast or ovarian
cancer with age at diagnosis are marked with black circles. Other cancers are marked in grey and accompanied by age at diagnosis, if known.
Index individual is marked with an arrow. Deceased individuals are indicated with a slash. Current ages of healthy females are marked if known.
Br, breast cancer; Co, colon; Kid, kidney; Mel, melanoma; Ov, ovarian cancer; To, tongue; Ute, uterus.
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and c.1100delC, five novel variants (Table 2) and one com-
mon polymorphism [see Supplementary Table S1 in Addi-
tional file 1] were identified in CHEK2. The novel non-
synonymous variant, c.1363G > A (Val455Ile), is based on
the computational predictions, and is likely benign.
PALB2 mutation analysis
In PALB2, altogether nine different variants, including
three novel ones, were identified [see Supplementary
Table S1 in Additional file 1]. Only one of the identified
variants reported previously, c.2586 + 58C > T, has been
associated with a 36% increase of BrCa risk (odds ratio
(OR): 1.36; 95% confidence intervals (CIs), 1.13-1.64; P =
0.001) in a Chinese population [25]. We identified the
c.2586 + 58C > T variant in 36 of 82 (43.9%) women. A
novel heterozygous c.814G > A variant was identified in
Skin 48
Co 58
Skin 70
Bil. Br 78
Sto 82
Bil. Br 59, 64
CHEK2, c.470T>C
PALB2, c.1676A>G
Family 129
Figure 2 Family 129 pedigree. Family pedigree of the index
individual with the identified CHEK2 c.470T > C and PALB2 c.1676A
> G variants. Individuals with breast cancer with age at diagnosis
are marked with black circles. Other cancers are marked in grey and
accompanied by age at diagnosis, if known. Index individual is
marked with an arrow. Deceased individuals are indicated with a
slash. Bil. Br, bilateral breast cancer; Co, colon; Sto, stomach.
Br 26
Ca
84
Pr 64
Br 48
CHEK2, c.470T>C
CHEK2, c.792+39C>T
CHEK2, c.1100delC
RAD50, c.2398-32A>G
37
595353
Family 110
Figure 3 Family 110 pedigree. Family pedigree of the index
individual with the identified CHEK2 c.470T > C, c.792 + 39C > T,
c.1100delC, and RAD50 c. 2398-32A > G variants. Individuals with
breast cancer with age at diagnosis are marked with black circles.
Other cancers are marked in grey and accompanied by age at
diagnosis, if known. Index individual is marked with an arrow.
Deceased individuals are indicated with a slash. Current ages of
healthy females are marked if known. Br, breast cancer; Ca, cancer
with unknown primary site; Pr, prostate.
Bil. Br 44
Br 44Br 52
CHEK2,
c.1100delC
17
52
Family 264
Figure 4 Family 264 pedigree. Family pedigree of the index
individual with the identified CHEK2 c.1100delC variant. Individuals
with breast cancer with age at diagnosis are marked with black
circles. Index individual is marked with an arrow. Deceased
individuals are indicated with a slash. Current ages of healthy females
are marked if known. Bil. Br, bilateral breast cancer; Br, breast cancer.
Br 45
Br 38
CHEK2, c.1100delC
PALB2, c.1676A>G
22
Family 265
Figure 5 Family 265 pedigree . Family pedigree of the index
individual with the identified CHEK2 c.1100delC and PALB2 c.1676A >
G variants. Individuals with breast cancer with age at diagnosis are
marked with black circles. Index individual is marked with an arrow.
Current ages of healthy females are marked if known. Br, breast cancer.
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1 of 82 (1.2%) women but not in population controls
(Tables 2 and 3). The c.814G > A variant carrying
woman had BrCa diagnosed at the age of 28 years, but no
other affected individuals were seen in her family. The
c.814G > A variant results in amino acid substitution of
glutamic acid to lysine at position 272, which causes a
significant change to side chain properties including size
and change of the charge to opposite. However, protein
predictions by PON-P suggest that variation is neutral.
The second novel heterozygous variant, c.1000T > G
(Tyr334Asp), was observed in 1 of 82 (1.2%) women and
in 4 of 380 (1.1%) population controls. The c.1000T > G
variant carrying woman had bilateral BrCa diagnosed at
the ages of 45 and 58 years and a family history of three
other cancers (Tables 2 and 3, Figure 6, Family 262). She
carried also the CHEK2 c.470T > C variant. However, the
protein predictions for the c.1000T > G (Tyr334Asp) var-
iant suggest it to be neutral. A third novel heterozygous
variant, c.2205A > G (Pro735Pro), is silent and likely to
be neutral. It was observed in 1 of 82 (1.2%) women
(Tables 2 and 3). Previously reported PALB2 missense
variants, c.1010T > C, c.1676A > G, c.2794G > A, and
c.2993G > A were identified here with frequencies from
1.2% to 12.2% in analyzed individuals (Tables 2 and 3)
but the variants have not been associated with BrCa risk
(an example of the family pedigree of the index individual
carrying the c.1676A > G variant in addition to the BRIP1
c.584T > C variant is presented in Figure 7, Family 131).
BRIP1, RAD50, and CDH1 mutation analysis
In BRIP1, two silent [see Supplementary Table S1 in
Additional file 1] and two missense variants (Tables 2
and 3) were identified. All of the identified variants have
been reported previously and they are likely to be neu-
tral. In RAD50, altogether seven sequence alterations
were observed [see Supplementary Table S1 in Addi-
tional file 1] and three of these were novel (Table 2).
The novel missense variant, c.1544A > G (Asp515Gly),
was observed in 1 of 82 (1.2%) women and in 4 of 384
(1.1%) population controls. The c.1544A > G variant
carrying woman had BrCa diagnosed at the age of 39
years and one affected first-degree relative (Table 3).
According to protein predictions, c.1544A > G variant is
likely to be neutral. Two other novel variants, c.2398-
32A > G and c.3475 + 33C > G, were both observed
with the frequency of 1 of 82 (1.2%) in analyzed indivi-
duals (Tables 2 and 3). In CDH1, 10 different sequence
alterations were identified [see Supplementary Table S1
in Additional file 1]. All of the variants have been
reported previously and they are likely neutral.
MicroRNA database and BLAST search for novel variants
No known miRNA target sites were found in the identi-
fied novel variant genomic positions. In BLAST search,
BRCA2 c.72A > T variant position was found to have
sequence similarities between rat and cow. RAD50
Bil. Br 45, 58
Br 57, Panc 83Sig 79
29 23
CHEK2, c.470T>C
PALB2, c.1000T>G
Family 262
Figure 6 Family 262 pedigree. Family pedigree of the index
individual with the identified CHEK2 c.470T > C and PALB2 c.1000T
> G variants. Individuals with breast cancer with age at diagnosis
are marked with black circles. Other cancers are marked in grey and
accompanied by age at diagnosis, if known. Index individual is
marked with an arrow. Deceased individuals are indicated with a
slash. Current ages of healthy females are marked if known. Bil. Br,
bilateral breast cancer; Br, breast cancer, Panc, pancreas; Si, sigma.
Bil. Br 54 Bil. Br 46 Br 48
85
43 37
PALB2, c.1676A>G
BRIP1, c.584T>C
Family 131
Figure 7 Family 131 pedigree. Family pedigree of the index
individual with the identified PALB2 c.1676A > G and BRIP1 c.584T >
C variants. Individuals with breast cancer with age at diagnosis are
marked with black circles. Index individual is marked with an arrow.
Deceased individuals are indicated with a slash. Current ages of
healthy females are marked if known. Bil. Br, bilateral breast cancer;
Br, breast cancer.
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c.1544A > G variant position shared similarities with
mouse, rat, cow and chicken. Three novel variant posi-
tions in CHEK2 exon 11 and the RAD50 c.3475 + 33C >
G variant shared sequence similarity between mouse, rat
and cow. Variants that occur in the genomic regions
that are conserved across species may indicate a patho-
genic role.
Discussion
In the present study, we screened BrCa susceptibility
genes in 82 Finnish high-risk HBOC individuals with no
known Finnish BRCA1/2-founder mutations. As genetic
counseling and surveillance is greatly needed for these
individuals and their families, we decided to study
BRCA1/2 in more detail and also to analyze five addi-
tional genes that had previously been associated with
BrCa risk.
The majority of known BRCA1/2 alterations are small
insertions and deletions or point mutations (BIC data-
base). Also, large genomic rearrangements have been
reported in both genes with varying frequencies in dif-
ferent populations [26]. In Finland, so far only Pylkäs et
al. have reported a large deletion in BRCA1 identified in
a Finnish OvCa family [27]. In our study, no deletions
or duplications were found in either BRCA1 or BRCA2
by MLPA, which suggests the existence of more
restricted alterations. A total of 16 different sequence
variants were identified from these two genes [see Sup-
plementary Table S1 in Additional file 1] and only one
of the identified variants, c.5095C > T in BRCA1, has
been classified as a clinically significant mutation in the
BIC database. In line with this classification, our BrCa
patient carrying this variant had a strong family history
of cancer (Tables 2 and 3, Figure 1, Family 249) and
two other variant carriers with BrCa were also observed
in the same family. The c.5095C > T mutation thus can
explain a fraction of the BrCa cases also in the Finnish
population. The clinical significance of the BRCA1
c.4883T > C variant in BrCa predisposition is uncertain
[28,29]. Our data support the idea that it is a low-pene-
trant risk allele, because the variant was observed to be
three times more common in analyzed high-risk indivi-
duals than healthy population controls (Tables 2 and 3).
Novel variant findings in BRCA2 (Tables 2 and 3) war-
rant additional studies, especially the novel missense
variant, c.72A > T (Leu24Phe), which was shown not to
be tolerated by protein prediction. Prediction indicated
that the substitution decreases the stability of the pro-
duced protein and this might be the mechanism behind
the disease for this variant. The amino acid position 24
is located near the N-terminal part of BRCA2. Amino
acids 1 to 40 interact with PALB2, and sequence var-
iants in this region have been shown to have effects on
the PALB2 and BRCA2 interaction and thus are
suspected to have a role in cancer predisposition [30].
The role of the three BRCA2 missense variants, c.8182G
> A, c.9976A > T, and c.10234A > G, in HBOC risk, is
uncertain [31-33]. All three heterozygous variants were
observed in two healthy women with a history of BrCa,
one carrying the c.9976A > T variant and the other
both the c.8182G > A and c.10234A > G variants
(Tables 2 and 3, Figure 8, Family 005). At this stage,
because we only have samples from the index indivi-
duals, no segregation analyses of the variants have been
performed, but these families clearly warrant additional
studies. In recent risk models, it has been suggested that
multiple low-risk variants within the same individual
may actually cause a significantly elevated risk for the
carrier [17]. The overall low frequency of new variants
identified in BRCA1/2 genes suggests that the present
protocol for testing 28 Finnish BRCA1/2-founder muta-
tions and PTT of the largest exons is adequate for clini-
cal use to detect the majority of harmful mutations in
these two genes in the Finnish population.
Two of the CHEK2 variants, c.470T > C and
c.1100delC, have been widely studied in BrCa predispo-
sition in Finland and elsewhere. Previous studies have
shown that the c.1100delC allele confers about a two-
fold elevated BrCa risk in women, whereas c.470T > C
is a lower risk variant [34,35]. Both variants also
Br 43, Sto 56
Bil. Br 43, 48
Lip 45
Bil. Br 54, 76Skin 75, Brain 
75,
Lung 81
BRCA2, c.8182G>A
BRCA2, c.10234A>G
Family 005
Figure 8 Family 005 pedigree. Family pedigree of the index
individual with the identified BRCA2 c.8182G > A and c.10234A > G
variants. Individuals with breast cancer with age at diagnosis are
marked with black circles. Other cancers are marked in grey and
accompanied by age at diagnosis, if known. Index individual is
marked with an arrow. Deceased individuals are indicated with a
slash. Bil. Br, bilateral breast cancer; Br, breast cancer; Sto, stomach.
Kuusisto et al. Breast Cancer Research 2011, 13:R20
http://breast-cancer-research.com/content/13/1/R20
Page 10 of 13
associate with other cancers in the Finnish population
[36-38]. In our study, two of the CHEK2 variants,
c.470T > C and c.1100delC, were identified in 10 out of
82 analyzed individuals (12.2%) suggesting that the con-
tribution of the two CHEK2 variants to BrCa risk is
remarkable in the high-risk Finnish BRCA1/2-founder
mutation-negative individuals. However, clinical screen-
ing of the CHEK2 variants has not yet been justified due
to unclear clinical consequences related to incomplete
segregation of the variants with BrCa in the high-risk
BrCa families [39,40]. Based on the findings of this
study, we agree that interpretation of the CHEK2 muta-
tion analysis results is very difficult, because many other
gene variants were also identified in individuals with
either c.470T > C or c.1100delC variants and some of
the variant carriers had not (yet) been diagnosed with
BrCa. Thus profound segregation analysis of the c.470T
> C and c.1100delC variants for BRCA1/2-founder
mutation-negative families would be needed to further
study clinical significance of these variants. Also the
novel variants identified in CHEK2 should be further
analyzed.
PALB2 has been associated with BrCa predisposition
in Finland by Erkko et al. [12] and the c.1592delT var-
iant was classified as a Finnish founder mutation. In this
study the founder deletion was not found, which is
probably explained by the limited number of analyzed
high-risk HBOC individuals. We identified two novel
PALB2 missense variants, c.814G > A (Glu272Lys) and
c.1000T > G (Tyr334Asp), in affected individuals (Tables
2 and 3). Protein predictions suggested a non-patho-
genic role of these substitutions but further studies are
needed to confirm these findings. None of the four pre-
viously reported PALB2 missense variants, c.1010T > C,
c.1676A > G, c.2794G > A, and c.2993G > A, have been
associated with BrCa risk [12,41]. Interestingly, these
variants were identified also together with other variants
in analyzed individuals (Tables 2 and 3). One of the
identified intronic variants, c.2586 + 58C > T, has been
associated with an increase of BrCa risk in a Chinese
population [25] but there is no evidence of that in the
Finnish population.
BRIP1 and RAD50 genes have been shown to have rare
BrCa associated variants in familial BrCa patients [14,42].
Here, BRIP1 mutation analysis revealed only previously
reported likely neutral variants. Whereas analysis of
RAD50 identified three novel sequence alterations,
including one missense variant, c.1544A > G (Asp515Gly)
(Tables 2 and 3). To further study the role of these novel
variants, additional analyses are needed. Germline muta-
tions in CDH1 have been previously found to associate
with hereditary diffuse gastric cancer syndrome, but
mutations have been also identified in familial invasive
lobular BrCa patients without hereditary diffuse gastric
cancer [15,43]. Here, only neutral variants were identi-
fied, and all of them have been reported earlier [see Sup-
plementary Table S1 in Additional file 1]. No clear
results were found that any of the identified genetic var-
iants in BRIP1, RAD50, or CDH1 would increase the
BrCa/OvCa risk in the analyzed high-risk Finnish HBOC
individuals.
Conclusions
In this study, 13.4% of the analyzed, high-risk BRCA1/2-
founder mutation-negative HBOC cases can be
explained by previously reported mutations in BrCa sus-
ceptibility genes. CHEK2 mutations, c.470T > C and
c.1100delC, make a considerable contribution (12.2%) to
these high-risk individuals but further segregation analy-
sis are needed to evaluate the clinical significance of
these mutations before applying them in clinical use.
Novel variant findings warrant additional studies with
special interest in the novel missense variant, BRCA2
c.72A > T (Leu24Phe), which was predicted to bear
untolerated mutations and to destabilize the protein.
The complex nature of HBOC addresses the need for
genome-wide approaches to further study these indivi-
duals and to create new tools for genetic counseling.
This study also confirmed that our current genetic test-
ing protocol for the 28 Finnish BRCA1/2-founder muta-
tions and PTT of the largest exons is sensitive enough
for clinical use in the majority of Finnish HBC/HBOC
individuals.
Additional material
Additional file 1: Supplementary Table S1. All of the identified 54
sequence alterations. Supplementary Table S1 include detailed
information about all of the identified sequence alterations.
Additional file 2: Supplementary Table S2. Identified breast cancer
associated variants in affected 71 individuals. Supplementary Table
S2 includes re-calculated frequencies for BRCA1 c.5095C > T, CHEK2
c.470T > C, and CHEK2 c.1100delC variants in affected 71 index
individuals (11 unaffected index individuals excluded).
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